Major Depressive Disorder research hub
16 indexed studies · 13 currently recruiting
- not yet recruitingPHASE3
Sustained Mood Improvement With Laughing Gas Exposure
This study looks into whether laughing gas (nitrous oxide) can help improve mood in people with severe depression that hasn't responded to other treatments. It compares laughing gas to oxygen over four weeks.
Canada - recruitingNA
Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression
This study is looking at a new way to treat severe depression that hasn't responded to usual treatments. It uses a special helmet to send gentle sound waves to the brain, aiming to improve mood. We want to see if it's safe and helpful.
Canada - not yet recruitingPHASE2
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
This study is looking at how having a helper (a 'monitor') with you affects psilocybin therapy for severe depression that hasn't responded to other treatments. Psilocybin comes from 'magic mushrooms' and is given with talking support.
Canada - authorisedTherapeutic exploratory (Phase II)
Psilocybin in treatment-resistant depression
This study is looking into whether a substance called psilocybin could help people with depression that hasn't responded to other treatments. Researchers want to see if it lessens depression symptoms one week after four weeks of treatment.
Austria - recruiting
A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.
This study looks at how well and how safely Vagus Nerve Stimulation (VNS) therapy works for people in the UK with severe depression that hasn’t improved with other treatments. It tracks their progress over several years after receiving the treatment.
Austria · Belgium · Germany - recruitingPHASE3
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
This study looks into new ways to treat severe depression when first treatments haven't worked well. It compares an intensive use of esketamine (a type of ketamine) with usual care, aiming to find better and faster relief for people struggling with depression.
Austria · Germany · Greece - recruitingPHASE2
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)
This study is exploring if a single dose of psilocybin, a compound from 'magic mushrooms,' could help people aged 18-65 with tough-to-treat depression and ongoing nerve pain. Researchers want to see if it's safe, and if it makes a difference to their symptoms.
Canada - recruitingPHASE2
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
This study looks at how psilocybin, found in 'magic mushrooms', might help people with depression that hasn't responded to other treatments. We'll use special scans to see if psilocybin changes brain connections and if this helps relieve depression.
Canada - recruitingNA
Olfactory and Brain Stimulations in Treatment-resistant Depression
This study looks at combining a type of brain stimulation with pleasant smells to help people with depression that hasn't responded to other treatments. Researchers want to see if this combination works better than brain stimulation alone for improving mood and enjoyment.
France - recruiting
Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
This study looks at the brains of people with depression to understand why some don't get better with usual treatments. We're using special scans to see how a chemical called dopamine works, hoping to find new ways to help those with hard-to-treat depression.
Canada - recruitingNA
A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients
This study compares two types of talking therapy, CBASP and BA, for adults with long-term depression that hasn't responded to other treatments. It aims to see which therapy works better to reduce depression symptoms over 16 weeks.
Germany - recruitingPHASE2
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
This study is looking at a new nasal spray called BPL-003 for people with depression that hasn't responded to other treatments. It will check if it's safe, how well it's tolerated, and how it affects the body, either alone or with common antidepressants.
United Kingdom - not yet recruiting
Mental Health Mission Mood Disorder Cohort Study
This study aims to understand why some people with depression respond to treatment better than others. It looks at various factors like symptoms, genes, and body chemistry to find new ways to improve diagnosis and treatment for mood disorders.
United Kingdom - authorisedTherapeutic exploratory (Phase II)
Efficacy of psilocybin and trazodone combination in treatment-resistant depression: a randomized controlled proof-of-concept study (PSILOTRAZ)
This study is looking into whether a combination of psilocybin and trazodone can help people with depression that hasn't responded to other treatments. Researchers want to see if this new approach can improve mood and reduce depression symptoms.
France - recruitingPHASE2
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
This study is testing a new film treatment (VLS-01) for depression that hasn't responded to other treatments. It will check if the film helps improve mood, how safe it is, and if people can tolerate it, compared to a dummy treatment.
United States · Australia · Canada - active not recruitingPHASE3
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
This study is looking at a new treatment called COMP360 (which contains psilocybin) for people with depression that hasn't improved with other treatments. Researchers want to see if it helps reduce depression symptoms and is safe, with participants receiving two doses alongside support.
United States · Canada · Czechia